Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

Ryan Specialty Holdings, Inc. appoints new co-presidents

Ryan Specialty Holdings, Inc. (NYSE: RYAN) has announced the appointment of Steve Keogh and Brendan Mulshine as co-presidents of the company. Both executives will report to CEO Tim Turner and succeed Jeremiah Bickham, who will transition to a strategic advisor role until the end of the year.

Steve Keogh, who joined Ryan Specialty in May 2025, brings over 30 years of industry experience, having held executive roles at Aon, including president of commercial risk solutions and president of U.S. commercial risk & health solutions. Brendan Mulshine, with over 30 years of insurance industry experience, has been with Ryan Specialty since 2012 and has served as the chief revenue officer.

The company's founder and executive chairman, Pat Ryan, expressed confidence in the new appointments, emphasizing the executives' track record of driving strong operational and financial results. CEO Tim Turner also expressed excitement about working closely with Keogh and Mulshine to maintain the company's momentum.

Additionally, Jeremiah Bickham, the outgoing president, received recognition for his exceptional service over nearly 14 years at Ryan Specialty. Both Pat Ryan and Tim Turner thanked Bickham for his dedication, hard work, and leadership, expressing gratitude for his contributions to the company.

Ryan Specialty Holdings, Inc., founded in 2010, is a leading international specialty insurance firm providing distribution, underwriting, product development, administration, and risk management services. The company operates as a wholesale broker and a managing underwriter with delegated authority from insurance carriers. The market has reacted to these announcements by moving the company's shares 0.14% to a price of $58.29. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS